oral sulopenem
FDA Advisors Seek Narrower Indication for Iterum’s Oral Sulopenem in Treating Uncomplicated Urinary Tract Infections
FDA, Iterum Therapeutics, oral sulopenem, uncomplicated urinary tract infections (uUTIs), antimicrobial resistance, Antimicrobial Drugs Advisory Committee (AMDAC)